Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Mozart Therapeutics presents MTX-101 trial outcomes, a dual-action CD8 Treg modifier for autoimmune treatment, at 2023 ACR Convergence
22 November 2023
Mozart Therapeutics shares trial results for MTX-101, a unique dual-action CD8 Treg adjuster used for treating autoimmune diseases, at the 2023 American College of Rheumatology Convergence.
Valuable Targets
4 min read
What are Chk1 inhibitors and how do you quickly get the latest development progress?
22 November 2023
Chk inhibitors can hinder the self-repair of tumor cells, thereby achieving the goal of enhancing the killing of tumor cells.
Latest Hotspot
3 min read
SCG Cell Therapy finds that SCG101 boosts tumor response and sustains antiviral effects in advanced liver cancer patients with HBV
22 November 2023
SCG Cell Therapy reports that SCG101 enhances tumor reactions and maintains consistent antiviral actions in patients having advanced hepatocellular carcinoma linked to HBV.
Clinical Progress
4 min read
An analysis of BNT-116's R&D progress and its clinical results presented at the 2023 SITC
22 November 2023
BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC).
Latest Hotspot
3 min read
Ionetix will supply Bayer with Actinium-225 (Ac-225), a therapeutic radioisotope
22 November 2023
Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.
Drug Insights
5 min read
Deep Scientific Insights on Vosoritide's R&D Progress, Mechanism of Action
22 November 2023
This article summarized the latest R&D progress of Vosoritide, the Mechanism of Action for Vosoritide, and the drug target R&D trends for Vosoritide.
Latest Hotspot
3 min read
Alpine Immune Sciences reveals new study results for Lupus treatment at 2023 Rheumatology Convergence
22 November 2023
Alpine Immune Sciences unveils fresh Acazicolcept study results for Systemic Lupus Erythematosus at 2023 Rheumatology Convergence by American College.
Clinical Progress
4 min read
Decoding LY-3410738: a comprehensive study of its R&D trends and its clinical results in 2023 AACR
20 November 2023
The phase 1 trial of LY3410738, a covalent mutant IDH inhibitor, in advanced IDH-mutant CCAs and other tumors was presented at the AACR Congress, paving the way for further outcome evaluation.
Latest Hotspot
3 min read
NImmune Biopharma released promising Phase 2 results for their lupus drug NIM-1324 at the 2023 ACR Convergence
20 November 2023
NImmune Biopharma unveiled promising early human trial results for NIM-1324, a Phase 2 drug candidate for Systemic Lupus Erythematosus, at the 2023 American College of Rheumatology Convergence.
Drug Insights
4 min read
Exploring Vincamine's Revolutionary R&D Successes
20 November 2023
This article summarized the latest R&D progress of Vincamine, the Mechanism of Action for Vincamine, and the drug target R&D trends for Vincamine.
Latest Hotspot
3 min read
Novo Nordisk unveils Wegovy® cardiac outcomes at AHA meeting and in NEJM
20 November 2023
Novo Nordisk presents cardiovascular results for Wegovy® (Semaglutide 2.4 mg) at the American Heart Association's scientific conference, also concurrently published in the New England Journal of Medicine.
Clinical Progress
4 min read
Exploring Ianalumab's R&D successes and its clinical results at the 2023 AACR
20 November 2023
The latest clinical findings of Ianalumab were unveiled at the 2023 AACR Congress, demonstrating its potential effect and setting the stage for subsequent investigations.